Recipharm, a contract development and manufacturing organization (CDMO), has entered into an agreement with Arcturus Therapeutics, a U.S. based clinical-stage messenger RNA medicines company focused infectious disease vaccines, to support the manufacture of ARCT-021, Arcturus’ COVID-19 vaccine candidate that is in an ongoing Phase I/II clinical trial.
The companies are working to secure commercial manufacturing production for 2021 and the future.
Thomas Eldered, CEO of Recipharm said: “We’re delighted to be able to support Arcturus Therapeutics on such an important project. Our experience in managing the complexity of biologic projects means that we are ideally placed to support from early phase discovery all the way through to successful commercialisation. We’re looking forward to working together and using our development and manufacturing expertise to continue to progress the project.”
